Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conjugated estrogens/bazedoxifene - Ligand Pharmaceuticals/Pfizer

Drug Profile

Conjugated estrogens/bazedoxifene - Ligand Pharmaceuticals/Pfizer

Alternative Names: Aprela; Bazedoxifene acetate/conjugated estrogens; Bazedoxifene/conjugated estrogens; Bazedoxifene/Premarin®; BZA/CE; CE/BZA; Conjugated estrogens/bazedoxifene acetate; Duavee; Duavive; Premarin®/bazedoxifene; SERM + Premarin

Latest Information Update: 04 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Developer Merck Sharp & Dohme; National Cancer Institute (USA); Northwestern University; Pfizer
  • Class Calcium regulators; Estradiol congeners; Hormonal replacements; Indoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Postmenopausal osteoporosis; Vasomotor symptoms
  • Phase II Breast cancer

Most Recent Events

  • 04 Feb 2019 Chemical structure information added
  • 24 Jun 2018 Biomarkers information updated
  • 01 Jan 2017 Phase-II clinical trials in Breast cancer (Newly diagnosed) in USA (PO) (NCT02694809)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top